We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+7.21%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$321M
AUM Growth
-$8.59M
(-2.6%)
Cap. Flow
-$23.2M
Cap. Flow
% of AUM
-7.22%
Top 10 Holdings %
Top 10 Hldgs %
95.56%
Holding
15
New
–
Increased
4
Reduced
7
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$9.39M |
| 2 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
+$154K |
| 3 |
Merck
MRK
|
+$75.1K |
| 4 |
IVC
Invacare Corporation
IVC
|
+$49.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UNIS
Unilife Corporation
UNIS
|
+$13.3M |
| 2 |
Orthofix Medical
OFIX
|
+$4.55M |
| 3 |
AVNS
Avanos Medical
AVNS
|
+$3.94M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$3.66M |
| 5 |
CONMED
CNMD
|
+$1.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enanta Pharmaceuticals
ENTA
$366M
| $47.4M | 14.79% |
1,013,847
-91,145
| -8% | -$3.66M |
|
2
Gilead Sciences
GILD
$162B
| $42.2M | 13.16% |
520,924
-11,510
| -2% | -$880K |
|
|
3
United Therapeutics
UTHR
$25.8B
| $40.6M | 12.66% |
346,511
+73,515
| +27% | +$9.39M |
|
|
SCMP
4
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $33.4M | 10.42% |
2,833,416
+13,708
| +0.5% | +$154K |
|
|
5
Merck
MRK
$322B
| $24.6M | 7.66% |
402,029
+1,238
| +0.3% | +$75.1K |
|
|
6
Orthofix Medical
OFIX
$477M
| $23M | 7.17% |
487,101
-96,706
| -17% | -$4.55M |
|
|
AVNS
7
DELISTED
Avanos Medical
AVNS
| $21.6M | 6.72% |
478,621
-92,343
| -16% | -$3.94M |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $20.1M | 6.26% |
147,127
-1,709
| -1% | -$258K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $17.7M | 5.52% |
1,124,528
+3,462
| +0.3% | +$49.4K |
|
|
10
CONMED
CNMD
$1.39B
| $10.1M | 3.13% |
191,601
-34,896
| -15% | -$1.75M |
|
|
VXRT
11
DELISTED
Vaxart
VXRT
| $1.94M | 0.61% |
257,848
| – | – |
|
|
STRR
12
DELISTED
Star Equity Holdings
STRR
| $1.15M | 0.36% |
6,684
| – | – |
|
|
JNP
13
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $1.11M | 0.34% |
243,128
| – | – |
|
|
UNIS
14
DELISTED
Unilife Corporation
UNIS
| – | – |
-77,079
| Closed | -$13.3M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, Krensavage Asset Management held 15 positions worth $321M, down 2.6% from $329M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Krensavage Asset Management withdrew a net $23.2M in Q3 2017, closing 1 position and reducing 7 holdings. Its most notable exit was Unilife Corporation, an estimated $13.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 74% a quarter earlier.
Against the trend, Krensavage Asset Management added an estimated $9.39M to United Therapeutics.
- Krensavage Asset Management added most to United Therapeutics in Q3 2017, an estimated $9.39M increase.
- Krensavage Asset Management's biggest Q3 2017 reduction was Orthofix Medical, cutting an estimated $4.55M.
- Krensavage Asset Management fully exited Unilife Corporation in Q3 2017, selling an estimated $13.3M.
- Krensavage Asset Management's ten largest holdings make up 96% of its $321M portfolio in Q3 2017.
- Krensavage Asset Management opened 0 new positions and closed 1 in Q3 2017.
- Krensavage Asset Management's portfolio value fell 2.6% quarter-over-quarter to $321M.
Based on Krensavage Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.